UID:
edoccha_9961276951202883
Format:
1 online resource (xiii, 388 pages) :
,
illustrations
ISBN:
0-323-91415-2
,
9780323914154
,
0323914152
Content:
Molecular Pharmaceutics and Nano Drug Delivery: Fundamentals and Challenges provides a thorough resource for both beginners and established scientists, bringing fundamental knowledge about key challenges of these carriers down to the molecular level. The book satisfies the need of availability of literature at single platform with the detailed knowledge to understand crucial aspects, such as regulatory, clinical, toxicological and the formulation requirements of these carriers. This is a valuable resource for graduates, pharmaceutical researchers and anyone working on aspects of pharmaceutics, molecular pharmaceutics and nano-drug/gene delivery. So called ‘novel drug delivery systems’ are numerous, with each having different approaches to their production, characterization and evaluation. The proper understanding of these dosage forms, as well as their critical attributes such as toxicity and regulatory requirements are aspects which researchers should know before they begin working on these carriers. This book provides this critical information.
Note:
Front Cover -- Molecular Pharmaceutics and Nano Drug Delivery -- Copyright Page -- Contents -- List of contributors -- Preface -- 1 Protein and enzyme-based nanoformulations -- 1.1 Introduction -- 1.2 Challenges associated with protein and enzymes delivery -- 1.3 Nanocarrier system for protein and enzyme delivery -- 1.3.1 Polymeric nanocarrier system -- 1.3.2 Lipidic nanocarrier system -- 1.3.3 Inorganic nanocarrier systems -- 1.4 Conclusion -- References -- 2 Vaccines and sera -- 2.1 Introduction -- 2.1.1 Vaccines -- 2.1.2 Revolution of vaccines development -- 2.1.2.1 18th century -- 2.1.2.2 19th century -- 2.2 Vaccine types and generations -- 2.2.1 Live attenuated vaccines -- 2.2.2 Subunit vaccine -- 2.2.3 Recombinant vaccine -- 2.2.4 Polysaccharide vaccine -- 2.2.5 Conjugate vaccines -- 2.2.6 Inactivated vaccines -- 2.2.7 Toxoid vaccines -- 2.3 Immunization -- 2.4 Immunology of vaccines -- 2.4.1 Immune system -- 2.4.2 General immune response mechanism -- 2.4.2.1 Activation of immunity -- 2.4.2.1.1 Immune response of live vaccine -- 2.4.2.1.2 Immune response of nonlive vaccine -- 2.5 Side effects and safety of vaccines -- 2.5.1 Adverse event following immunization detection: to strengthen vaccine safety monitoring in all countries -- 2.6 Vaccine preparation -- 2.6.1 Examples of vaccine preparations -- 2.6.1.1 Measles vaccine -- 2.6.1.2 Diphtheria vaccine -- 2.6.1.3 Tetanus vaccine -- 2.6.1.4 Influenza vaccine -- 2.6.1.5 Hepatitis vaccine -- 2.6.1.6 Haemophilus influenzae type B -- 2.6.1.7 BCG vaccine -- 2.6.1.8 Smallpox vaccine -- 2.6.1.9 Rabies vaccine -- 2.7 Vaccines evaluation and standardization -- 2.7.1 Evaluation of vaccines -- 2.7.2 Standardization of vaccines -- 2.8 Regulatory consideration of vaccines -- 2.9 Licensed vaccines -- 2.10 Sera -- 2.11 Revolutions in serum therapy -- 2.12 General method of preparation of sera.
,
2.12.1 Antibacterial sera -- 2.12.2 Antiviral sera -- 2.13 Evaluation of sera -- 2.14 Standardization of sera -- 2.15 Regulatory consideration of sera -- 2.16 Marketed products of vaccines and sera -- 2.17 Challenges to vaccine and sera success -- 2.18 New approaches for vaccines and sera -- 2.18.1 Nucleic acid -- 2.18.1.1 mRNA vaccine -- 2.18.1.2 DNA vaccine -- 2.18.2 Viral vectors -- 2.18.3 Recombinant viral vector -- 2.18.4 Virus-like particles -- 2.18.5 Tuberculosis vaccine -- 2.18.6 Cancer vaccine -- 2.18.6.1 Neoantigen vaccines -- 2.18.6.2 RNA-based vaccines -- 2.18.6.3 Peptide-based vaccines -- 2.18.6.4 Dendritic cell-based vaccines -- 2.18.7 HIV vaccine -- 2.18.8 Malaria vaccines -- 2.18.9 Dengue vaccines -- 2.18.9.1 Nanoparticle-based vaccines -- 2.18.9.2 Tetravalent dengue vaccine -- 2.18.9.3 Nonstructural protein targets -- 2.18.9.4 Vaccines with additives -- 2.18.9.5 RNA-based vaccines -- 2.19 Conclusion -- References -- 3 Aptamers and antisense oligonucleotide-based delivery -- 3.1 What is the aptamer? -- 3.2 Aptamer design -- 3.2.1 Systematic evolution of ligands by exponential enrichment -- 3.2.2 In silico systematic evolution of ligands by exponential enrichment -- 3.2.3 Machine learning-based methods -- 3.2.3.1 Data preparation -- 3.2.3.2 Feature extraction -- 3.2.3.2.1 Sequence-based features -- 3.2.3.2.2 Structure-based features -- 3.2.3.2.3 Energy-based features -- 3.2.3.3 Feature selection -- 3.2.3.3.1 Prediction models of aptamer-target interaction -- 3.2.3.4 Model evaluation -- 3.2.3.4.1 Accuracy: fraction of correctly classified samples -- 3.2.3.4.2 Sensitivity -- 3.2.3.4.3 Specificity -- 3.3 Drug delivery by aptamers -- 3.4 Binding to different molecules -- 3.4.1 Aptamers and liposomes -- 3.4.2 Aptamers and chitosan -- 3.4.3 Aptamers and graphene -- 3.4.4 Aptamers and magnetic manoparticles -- References.
,
4 Monoclonal antibodies: recent development in drug delivery -- 4.1 Introduction -- 4.2 The molecular mechanisms of therapeutic antibody -- 4.3 Advantages and disadvantages of mAbs -- 4.4 Pharmacokinetics versus tumor targeting -- 4.5 Approaches for developing targeted monoclonal antibodies -- 4.5.1 XenoMouse hybridoma technology -- 4.5.2 Phage display for the production of human mAbs -- 4.5.3 Transgenic mice that produce human monoclonal antibodies -- 4.5.4 Antibody technique based on single B cells -- 4.5.5 Humanization of mAbs -- 4.5.6 Generation of humanized mAbs -- 4.5.7 Human and humanized mAbs -- 4.5.8 Stereospecific monoclonal antibodies -- 4.6 Novel drug delivery systems for mAbs -- 4.6.1 Nanoparticles -- 4.6.2 Microspheres -- 4.6.3 Hydrogels -- 4.6.4 Other delivery systems -- 4.7 Formulation challenges of mAbs -- 4.8 Future trends of mAbs -- 4.9 Conclusion -- References -- 5 Hormonal delivery systems -- 5.1 Introduction -- 5.2 Hormones as pharmacotherapeutics -- 5.2.1 Insulin -- 5.2.1.1 Diabetes mellitus -- 5.2.1.2 Diabetic ketoacidosis -- 5.2.1.3 Hyperglycemic hyperosmolar state -- 5.2.1.4 Cystic fibrosis-related diabetes -- 5.2.1.5 Insulinoma -- 5.2.1.6 Growth hormone deficiency -- 5.2.1.7 Hyperkalemia -- 5.2.1.8 Diabetic gastroparesis -- 5.2.1.9 Hypertriglyceridemia -- 5.2.1.10 Lipodystrophy -- 5.2.1.11 Other conditions -- 5.2.2 Glucagon -- 5.2.3 Thyroid hormones -- 5.2.4 Corticosteroids -- 5.2.4.1 Inflammatory conditions -- 5.2.4.2 Autoimmune disorders -- 5.2.4.3 Allergic reactions -- 5.2.4.4 Cancer -- 5.2.4.5 Adrenal insufficiency -- 5.2.5 Growth hormone -- 5.2.6 Estrogen hormone -- 5.2.6.1 Hormone replacement therapy -- 5.2.6.2 Selective estrogen receptor modulators -- 5.2.6.3 Aromatase inhibitors -- 5.2.7 Progesterone hormone -- 5.2.7.1 Menstrual irregularities -- 5.2.7.2 Infertility -- 5.2.7.3 Miscarriage.
,
5.2.7.4 Endometrial cancer -- 5.2.8 Testosterone hormone -- 5.2.9 Follicle stimulating hormone -- 5.2.10 Luteinizing hormone-releasing hormone -- 5.2.11 Human chorionic gonadotropin hormone -- 5.3 Novel drug delivery systems for hormones -- 5.3.1 Microparticles -- 5.3.2 Liposomes -- 5.3.3 Polymeric nanoparticles -- 5.3.4 Lipid nanoparticles -- 5.3.5 Nanoemulsion -- 5.3.6 Self-emulsifying drug delivery systems -- 5.3.7 Nanogels -- 5.3.8 Dendrimers -- 5.3.9 Inorganic nanoparticles -- 5.3.10 Transferosomes -- 5.4 Conclusion and future perspectives -- References -- 6 Vesicular drug delivery systems: a novel approach in current nanomedicine -- 6.1 Introduction -- 6.2 Type of vesicles -- 6.2.1 Liposomes -- 6.2.2 Niosomes -- 6.2.3 Polymersomes -- 6.3 Engineered vesicles for therapeutic purposes -- 6.3.1 Transformable drug delivery vesicles -- 6.3.2 Actively targeted vesicles -- 6.3.3 Multifunctional vesicles -- 6.4 Pharmaceutical application of vesicles -- 6.4.1 Cancer therapy -- 6.4.2 Diagnostic -- 6.4.3 Gene delivery -- 6.4.4 Immunotherapy and vaccines -- 6.5 Conclusions and outlooks -- References -- 7 Polymeric micelles in drug delivery and targeting -- Abbreviations -- 7.1 Introduction -- 7.2 Polymeric micelles -- 7.2.1 Polymer-drug conjugates -- 7.2.2 Drug-encapsulated polymeric micelles -- 7.2.3 Polyion complex micelles -- 7.3 Characterization and evaluation of polymeric micelles -- 7.3.1 Particle size, size distribution, and zeta potential -- 7.3.2 Morphology and shape -- 7.3.3 Critical micelle concentration -- 7.3.4 Stability -- 7.3.5 In vitro drug release studies -- 7.4 Application of polymeric micelles in drug delivery -- 7.4.1 Solubility enhancement -- 7.4.2 Passive targeting -- 7.4.3 Active targeting -- 7.4.3.1 Aptamer-coupled polymeric micelles -- 7.4.3.2 Folic acid-coupled polymeric micelles.
,
7.4.3.3 Hyaluronic acid-coupled polymeric micelles -- 7.4.3.4 Transferrin-coupled polymeric micelles -- 7.4.4 Stimuli-responsive polymeric micelles -- 7.4.4.1 pH-responsive polymeric micelles -- 7.4.4.2 Redox-sensitive polymeric micelles -- 7.4.4.3 Enzyme-responsive polymeric micelles -- 7.4.4.4 Thermoresponsive polymeric micelles -- 7.5 Challenges associated with clinical translation -- 7.6 Conclusion -- Conflict of interest -- References -- 8 Physicochemical characterization of drug delivery systems based on nanomaterials -- 8.1 Introduction -- 8.2 Nanomaterial shape/morphology -- 8.3 Size average, distribution, and nanomaterial concentration -- 8.4 Nanomaterial surface properties -- 8.5 Nanomaterial-active pharmaceutical ingredient structure, composition, and crystal form -- 8.6 Active pharmaceutical ingredient content -- 8.7 Active pharmaceutical ingredient degradation products, other impurities, and stability assessment -- 8.8 Active pharmaceutical ingredient release assay -- References -- 9 Inorganic and metal-based nanoparticles -- 9.1 Introduction -- 9.2 Enhanced permeability and retention effect -- 9.3 Blood-brain barrier -- 9.3.1 History of blood-brain barrier -- 9.3.2 Cells of the blood-brain barrier -- 9.3.2.1 Endothelial cells -- 9.3.2.2 Pericytes -- 9.3.2.3 Astrocytes -- 9.3.2.4 Tight junctions -- 9.3.2.5 Mural cells -- 9.3.3 Regulation of the blood-brain barrier -- 9.3.4 Disturbance of the blood-brain barrier in the central nervous system disorder -- 9.3.4.1 Paracellular pathway -- 9.3.4.2 Transcellular pathway -- 9..3.4.3 Passive diffusion -- 9.3.4.4 Active efflux -- 9.3.4.5 Receptor-mediated transcytosis -- 9.3.4.6 Carrier-mediated transport -- 9.3.4.7 Charged compound interaction -- 9.4 Neurological disease -- 9.4.1 Alzheimer's disease -- 9.4.1.1 Iron oxide nanoparticles -- 9.4.1.2 Gadolinium nanoparticles.
,
9.4.2 Parkinson's disease.
Additional Edition:
ISBN 9780323919241
Additional Edition:
Print version: Molecular pharmaceutics and nano drug delivery ISBN 9780323919241
Language:
English
Bookmarklink
